9.85
1.05 (11.93%)
| Penutupan Terdahulu | 8.80 |
| Buka | 8.73 |
| Jumlah Dagangan | 318,471 |
| Purata Dagangan (3B) | 210,296 |
| Modal Pasaran | 258,169,568 |
| Harga / Jualan (P/S) | 4.25 |
| Harga / Buku (P/B) | 5.05 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 5 Nov 2025 |
| Margin Keuntungan | -97.49% |
| Margin Operasi (TTM) | -108.82% |
| EPS Cair (TTM) | -2.14 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 14.70% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 72.70% |
| Nisbah Semasa (MRQ) | 14.82 |
| Aliran Tunai Operasi (OCF TTM) | -41.02 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -25.25 M |
| Pulangan Atas Aset (ROA TTM) | -26.88% |
| Pulangan Atas Ekuiti (ROE TTM) | -76.01% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Medical Devices (US) | Bercampur | Bercampur |
| Medical Devices (Global) | Bercampur | Bercampur | |
| Stok | CVRx, Inc. | Menaik | Menurun |
AISkor Stockmoo
| Konsensus Penganalisis | 3.0 |
| Aktiviti Orang Dalam | -4.0 |
| Volatiliti Harga | -2.0 |
| Purata Bergerak Teknikal | 1.5 |
| Osilator Teknikal | -0.5 |
| Purata | -0.40 |
|
CVRx Inc is a commercial-stage medical device company focused on developing, manufacturing, and commercializing minimally invasive neuromodulation solutions for patients with cardiovascular diseases. Its proprietary platform technology, Barostim, is designed to leverage the power of the brain to address the imbalance of the Autonomic Nervous System, which causes heart failure and other cardiovascular diseases. Barostim provides Baroreflex Activation Therapy which in turn triggers an autonomic response to the heart. The majority of revenue is derived from the USA market. |
|
| Sektor | Healthcare |
| Industri | Medical Devices |
| Gaya Pelaburan | Small Growth |
| % Dimiliki oleh Orang Dalam | 4.26% |
| % Dimiliki oleh Institusi | 73.63% |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 13.00 (Cantor Fitzgerald, 31.98%) | Beli |
| Median | 12.00 (21.83%) | |
| Rendah | 11.00 (Canaccord Genuity, 11.68%) | Beli |
| Purata | 12.00 (21.83%) | |
| Jumlah | 2 Beli | |
| Harga Purata @ Panggilan | 10.05 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Canaccord Genuity | 06 Nov 2025 | 11.00 (11.68%) | Beli | 10.05 |
| Cantor Fitzgerald | 06 Nov 2025 | 13.00 (31.98%) | Beli | 10.05 |
| Nama | Purata Belian ($) | Purata Jualan ($) | Jumlah Net | Jumlah Nilai Bersih ($) |
|---|---|---|---|---|
| JOHNSON & JOHNSON | - | 9.84 | -8,537 | -83,941 |
| Jumlah Keseluruhan Kuantiti Bersih | -8,537 | |||
| Jumlah Keseluruhan Nilai Bersih ($) | -83,941 | |||
| Purata Pembelian Keseluruhan ($) | - | |||
| Purata Jualan Keseluruhan ($) | 9.84 | |||
| Nama | Pemegang | Tarikh | Jenis | Kuantiti | Harga | Nilai ($) |
|---|---|---|---|---|---|---|
| JOHNSON & JOHNSON | 26 Nov 2025 | Jual (-) | 6,337 | 9.83 | 62,293 | |
| JOHNSON & JOHNSON | 24 Nov 2025 | Jual (-) | 2,200 | 9.84 | 21,648 |
| Tarikh | Jenis | Butiran |
|---|---|---|
| 19 Nov 2025 | Pengumuman | CVRx to Participate at the Piper Sandler 37th Annual Healthcare Conference |
| 05 Nov 2025 | Pengumuman | CVRx Reports Third Quarter 2025 Financial and Operating Results |
| 04 Nov 2025 | Pengumuman | CVRx to Present at the Jefferies Global Healthcare Conference in London |
| 22 Oct 2025 | Pengumuman | CVRx to Report Third Quarter 2025 Financial and Operating Results and Host Conference Call on Nov. 5, 2025 |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |